Vertex, Inc. shares have plunged over 60% YTD, but valuation is now compelling after a post-earnings dip. Learn more about VERX stock here.

One key figure, however, indicates otherwise as sales for Journavx were at $20 million for the period, coming up $3 million ...

Q3 2025 Earnings Call Transcript November 3, 2025 Vertex, Inc. reports earnings inline with expectations. Reported EPS is ...

Baird lowered the firm’s price target on Vertex (VERX) to $25 from $32 and keeps a Neutral rating on the shares. The firm updated its model ...

Vertex (NASDAQ: VERX) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table below ...

Vertex Pharmaceuticals reported on Monday that it beat Wall Street estimates for third-quarter results, driven by strong demand for its cystic fibrosis treatments and early contributions from newer ...

Analysts expect the Boston, Massachusetts-based company to report quarterly earnings at $4.58 per share, up from $4.38 per share in the year-ago period. The consensus estimate for Vertex ...